| Dr Robert Macdonald Iv, MD | |
|
400 W 16th St, Pueblo, CO 81003-2745 | |
| (719) 584-4595 | |
| (719) 584-4861 |
| Full Name | Dr Robert Macdonald Iv |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 400 W 16th St, Pueblo, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306829486 | NPI | - | NPPES |
| 01346162 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 34616 (Colorado) | Primary |
| Entity Name | Usacs Of Colorado Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760415871 PECOS PAC ID: 4981507571 Enrollment ID: O20040130000439 |
News Archive
Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution.
According to the National Centre for Health Statistics, despite being one of the richest countries in the world, America has dropped to 42nd place in the world rankings of life expectancy.
Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.
UC biologists have turned to amphibian sources - specifically frogs and tadpoles - to help shed light on how early stressors in the womb and shortly after birth may play a part in the onset of adult diseases such as diabetes and cardiovascular disease.
› Verified 2 days ago
| Entity Name | Parkview Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730144684 PECOS PAC ID: 0143116673 Enrollment ID: O20040223001035 |
News Archive
Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution.
According to the National Centre for Health Statistics, despite being one of the richest countries in the world, America has dropped to 42nd place in the world rankings of life expectancy.
Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.
UC biologists have turned to amphibian sources - specifically frogs and tadpoles - to help shed light on how early stressors in the womb and shortly after birth may play a part in the onset of adult diseases such as diabetes and cardiovascular disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Macdonald Iv, MD 400 W 16th St, Pueblo, CO 81003-2745 Ph: (719) 584-4595 | Dr Robert Macdonald Iv, MD 400 W 16th St, Pueblo, CO 81003-2745 Ph: (719) 584-4595 |
News Archive
Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution.
According to the National Centre for Health Statistics, despite being one of the richest countries in the world, America has dropped to 42nd place in the world rankings of life expectancy.
Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.
UC biologists have turned to amphibian sources - specifically frogs and tadpoles - to help shed light on how early stressors in the womb and shortly after birth may play a part in the onset of adult diseases such as diabetes and cardiovascular disease.
› Verified 2 days ago
Mary Russo, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Teresa Kay Braden, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 311 W 14th St, Pueblo, CO 81003 Phone: 719-595-7585 Fax: 719-595-7589 | |
Kyle Delbar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4595 | |
Elizabeth Brittany Skewes, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Michael Todd Duzan, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 401 W Northern Ave, Pueblo, CO 81004 Phone: 719-553-0400 Fax: 719-553-0401 | |
Dr. Scott W Calcagno, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Dr. David James Joyce, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-584-4861 |